UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/666,642	09/21/2000	Hu Yang	2039.008200	9201
32223 7590 05/14/2007 CHEVRON PHILLIPS CHEMICAL COMPANY LP LAW DEPARTMENT - IP P.O BOX 4910 THE WOODLANDS, TX 77387-4910			EXAMINER	
			MULLIS, JEFFREY C	
			ART UNIT	PAPER NUMBER
,			1711	
			MAIL DATE	DELIVERY MODE
			05/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Supplemental	Application No.	Applicant(s)				
Notice of Allowability	09/666,642	YANG ET AL.				
Notice of Allowability	Examiner	Art Unit				
	Jeffrey C. Mullis	1711				
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Refer to the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this or other appropriate communica IGHTS. This application is subje	application. If not included tion will be mailed in due course. THIS				
1. This communication is responsive to <u>1-30-07</u> .						
2. X The allowed claim(s) is/are 1-4.11.15-30.37.41-63.65.66.7	0-73,80,84-91,98 and 102-115.					
3. ☐ Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this national stage application from the						
International Bureau (PCT Rule 17.2(a)).						
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.						
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.						
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.						
(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached						
1) hereto or 2) to Paper No./Mail Date						
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date						
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).						
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
	•					
	ı					
Attachment(s)						
1. Notice of References Cited (PTO-892)	5. Notice of Inform	al Patent Application				
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. 四 Interview Summ Paper No./Mail	ary (PTO-413), Date				
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🗷 Examiner's Ame	endment/Comment				
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 		ement of Reasons for Allowance				
•	9.					
	·	•				
•						
		·				

Application/Control Number: 09/666,642 Page 2

Art Unit: 1711

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

In the specification—

Amend the specification at page 7, lines 1-10 as shown below--

Art Unit: 1711

The oxygen barrier polymer is any polymer-generally viewed as providing a barrier to oxygen passage, e.g. a 1 mil layer consisting essentially of the oxygen barrier polymer has an oxygen transmission rate of less than about 100 ce/m2/day at room temperature under 1 atm O2 and 0% humidity. Preferably, the oxygen barrier polymer is selected from polymers or copolymers of vinyl alcohol (such as ethylene/vinyl-alcohol-copolymer (EVOH)), polyesters (such as polyethylene terephthalate (PET) or polyethylene naphthalate (PEN)), polymers or copolymers of vinylidene dichloride (such as polyvinylidene dichloride (PVDC)), polymers or copolymers of epoxies, polysulfones, polymers or copolymers of acrylonitrile (such as polyacrylonitrile (PAN)), polymers or copolymers of isocyanates, or polyamides other than MXD6. In one preferred embodiment, the oxygen barrier polymer is poly(ethylene vinyl alcohol) (EVOH). In still another preserved embodiment, the oxygen barrier polymer is polyacrylonitrile (PAN) or a copolymer comprising acrylonitrile. In a further preferred embodiment, the oxygen barrier polymer is poly(vinylidene dichloride) (PVDC). In yet an additional preferred embodiment, the oxygen barrier polymer is polyethylene terephthalate (PET). In yet a further preferred embodiment, the oxygen barrier polymer is polyethylene naphthalate (PEN). In still an additional preferred embodiment, the oxygen barrier polymer is a polyamide other than MXD6. The polyamide can be aliphatic or aromatic. Preferred polyamides include nylon 6; nylon 6,6; amorphous polyamide; and nylon 6,12.

Art Unit: 1711

Authorization for this examiner's amendment was given in a telephone interview with KaRan Reed on 4-16-07.

JCM

4-10-07

PRIMEROUP TOBOL 17 11